283 related articles for article (PubMed ID: 21827418)
21. Mitochondrial DNA Alterations in Glioblastoma (GBM).
Leão Barros MB; Pinheiro DDR; Borges BDN
Int J Mol Sci; 2021 May; 22(11):. PubMed ID: 34072607
[TBL] [Abstract][Full Text] [Related]
22. Targeting core (mutated) pathways of high-grade gliomas: challenges of intrinsic resistance and drug efflux.
Lin F; de Gooijer MC; Hanekamp D; Brandsma D; Beijnen JH; van Tellingen O
CNS Oncol; 2013 May; 2(3):271-88. PubMed ID: 25054467
[TBL] [Abstract][Full Text] [Related]
23. The role of glioma stem cells in chemotherapy resistance and glioblastoma multiforme recurrence.
Auffinger B; Spencer D; Pytel P; Ahmed AU; Lesniak MS
Expert Rev Neurother; 2015; 15(7):741-52. PubMed ID: 26027432
[TBL] [Abstract][Full Text] [Related]
24. Ras pathway activation in gliomas: a strategic target for intranasal administration of perillyl alcohol.
da Fonseca CO; Linden R; Futuro D; Gattass CR; Quirico-Santos T
Arch Immunol Ther Exp (Warsz); 2008; 56(4):267-76. PubMed ID: 18726148
[TBL] [Abstract][Full Text] [Related]
25. Combined treatment of Nimotuzumab and rapamycin is effective against temozolomide-resistant human gliomas regardless of the EGFR mutation status.
Chong DQ; Toh XY; Ho IA; Sia KC; Newman JP; Yulyana Y; Ng WH; Lai SH; Ho MM; Dinesh N; Tham CK; Lam PY
BMC Cancer; 2015 Apr; 15():255. PubMed ID: 25886314
[TBL] [Abstract][Full Text] [Related]
26. Benzyl isothiocyanate (BITC) induces apoptosis of GBM 8401 human brain glioblastoma multiforms cells via activation of caspase-8/Bid and the reactive oxygen species-dependent mitochondrial pathway.
Shang HS; Shih YL; Lu TJ; Lee CH; Hsueh SC; Chou YC; Lu HF; Liao NC; Chung JG
Environ Toxicol; 2016 Dec; 31(12):1751-1760. PubMed ID: 28675694
[TBL] [Abstract][Full Text] [Related]
27. Inhibition of glycolytic metabolism in glioblastoma cells by Pt3glc combinated with PI3K inhibitor via SIRT3-mediated mitochondrial and PI3K/Akt-MAPK pathway.
Wang G; Fu XL; Wang JJ; Guan R; Sun Y; Tony To SS
J Cell Physiol; 2019 May; 234(5):5888-5903. PubMed ID: 29336479
[TBL] [Abstract][Full Text] [Related]
28. Toward an effective strategy in glioblastoma treatment. Part I: resistance mechanisms and strategies to overcome resistance of glioblastoma to temozolomide.
Messaoudi K; Clavreul A; Lagarce F
Drug Discov Today; 2015 Jul; 20(7):899-905. PubMed ID: 25744176
[TBL] [Abstract][Full Text] [Related]
29. REV3L confers chemoresistance to cisplatin in human gliomas: the potential of its RNAi for synergistic therapy.
Wang H; Zhang SY; Wang S; Lu J; Wu W; Weng L; Chen D; Zhang Y; Lu Z; Yang J; Chen Y; Zhang X; Chen X; Xi C; Lu D; Zhao S
Neuro Oncol; 2009 Dec; 11(6):790-802. PubMed ID: 19289490
[TBL] [Abstract][Full Text] [Related]
30. Hypoxia-mediated mitochondria apoptosis inhibition induces temozolomide treatment resistance through miR-26a/Bad/Bax axis.
Ge X; Pan MH; Wang L; Li W; Jiang C; He J; Abouzid K; Liu LZ; Shi Z; Jiang BH
Cell Death Dis; 2018 Nov; 9(11):1128. PubMed ID: 30425242
[TBL] [Abstract][Full Text] [Related]
31. The Phenomenon of Multidrug Resistance in Glioblastomas.
Chernov AN; Alaverdian DA; Galimova ES; Renieri A; Frullanti E; Meloni I; Shamova OV
Hematol Oncol Stem Cell Ther; 2022 Jun; 15(2):1-7. PubMed ID: 34216549
[TBL] [Abstract][Full Text] [Related]
32. MiR-144 overexpression as a promising therapeutic strategy to overcome glioblastoma cell invasiveness and resistance to chemotherapy.
Cardoso AMS; Sousa M; Morais CM; Oancea-Castillo LR; Régnier-Vigouroux A; Rebelo O; Tão H; Barbosa M; Pedroso MCL; Jurado AS
Hum Mol Genet; 2019 Aug; 28(16):2738-2751. PubMed ID: 31087038
[TBL] [Abstract][Full Text] [Related]
33. FERMT3 contributes to glioblastoma cell proliferation and chemoresistance to temozolomide through integrin mediated Wnt signaling.
Lu C; Cui C; Liu B; Zou S; Song H; Tian H; Zhao J; Li Y
Neurosci Lett; 2017 Sep; 657():77-83. PubMed ID: 28778805
[TBL] [Abstract][Full Text] [Related]
34. Chemoresistance in high-grade gliomas: relevance of adenosine signalling in stem-like cells of glioblastoma multiforme.
Garrido W; Rocha JD; Jaramillo C; Fernandez K; Oyarzun C; San Martin R; Quezada C
Curr Drug Targets; 2014; 15(10):931-42. PubMed ID: 25174341
[TBL] [Abstract][Full Text] [Related]
35. Chemoresistance caused by the microenvironment of glioblastoma and the corresponding solutions.
Zhang X; Ding K; Wang J; Li X; Zhao P
Biomed Pharmacother; 2019 Jan; 109():39-46. PubMed ID: 30391707
[TBL] [Abstract][Full Text] [Related]
36. Temozolomide resistance in glioblastoma occurs by miRNA-9-targeted PTCH1, independent of sonic hedgehog level.
Munoz JL; Rodriguez-Cruz V; Ramkissoon SH; Ligon KL; Greco SJ; Rameshwar P
Oncotarget; 2015 Jan; 6(2):1190-201. PubMed ID: 25595896
[TBL] [Abstract][Full Text] [Related]
37. Targeting metabolic remodeling in glioblastoma multiforme.
Wolf A; Agnihotri S; Guha A
Oncotarget; 2010 Nov; 1(7):552-62. PubMed ID: 21317451
[TBL] [Abstract][Full Text] [Related]
38. Bortezomib-induced sensitization of malignant human glioma cells to vorinostat-induced apoptosis depends on reactive oxygen species production, mitochondrial dysfunction, Noxa upregulation, Mcl-1 cleavage, and DNA damage.
Premkumar DR; Jane EP; Agostino NR; DiDomenico JD; Pollack IF
Mol Carcinog; 2013 Feb; 52(2):118-33. PubMed ID: 22086447
[TBL] [Abstract][Full Text] [Related]
39. The unfolded protein response regulator GRP78/BiP as a novel target for increasing chemosensitivity in malignant gliomas.
Pyrko P; Schönthal AH; Hofman FM; Chen TC; Lee AS
Cancer Res; 2007 Oct; 67(20):9809-16. PubMed ID: 17942911
[TBL] [Abstract][Full Text] [Related]
40. Mitochondria-Targeted Doxorubicin: A New Therapeutic Strategy against Doxorubicin-Resistant Osteosarcoma.
Buondonno I; Gazzano E; Jean SR; Audrito V; Kopecka J; Fanelli M; Salaroglio IC; Costamagna C; Roato I; Mungo E; Hattinger CM; Deaglio S; Kelley SO; Serra M; Riganti C
Mol Cancer Ther; 2016 Nov; 15(11):2640-2652. PubMed ID: 27466354
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]